GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » HTG Molecular Diagnostics Inc (OTCPK:HTGMQ) » Definitions » Net-Net Working Capital

HTG Molecular Diagnostics (HTG Molecular Diagnostics) Net-Net Working Capital : $-1.20 (As of Mar. 2023)


View and export this data going back to 2015. Start your Free Trial

What is HTG Molecular Diagnostics Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

HTG Molecular Diagnostics's Net-Net Working Capital for the quarter that ended in Mar. 2023 was $-1.20.

The industry rank for HTG Molecular Diagnostics's Net-Net Working Capital or its related term are showing as below:

HTGMQ's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 5.64
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

HTG Molecular Diagnostics Net-Net Working Capital Historical Data

The historical data trend for HTG Molecular Diagnostics's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HTG Molecular Diagnostics Net-Net Working Capital Chart

HTG Molecular Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.90 46.13 22.89 7.03 0.61

HTG Molecular Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.30 -0.67 -4.68 0.61 -1.20

Competitive Comparison of HTG Molecular Diagnostics's Net-Net Working Capital

For the Diagnostics & Research subindustry, HTG Molecular Diagnostics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HTG Molecular Diagnostics's Price-to-Net-Net-Working-Capital Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, HTG Molecular Diagnostics's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where HTG Molecular Diagnostics's Price-to-Net-Net-Working-Capital falls into.



HTG Molecular Diagnostics Net-Net Working Capital Calculation

HTG Molecular Diagnostics's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net-Net Working Capital(A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(12.211+0.75 * 1.422+0.5 * 0.909-12.386
-0-0)/2.2139
=0.61

HTG Molecular Diagnostics's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2023 is calculated as

Net-Net Working Capital(Q: Mar. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(6.563+0.75 * 1.132+0.5 * 0.655-10.391
-0-0)/2.21408
=-1.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


HTG Molecular Diagnostics  (OTCPK:HTGMQ) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


HTG Molecular Diagnostics Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of HTG Molecular Diagnostics's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


HTG Molecular Diagnostics (HTG Molecular Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
3430 E. Global Loop, Tucson, AZ, USA, 85706
HTG Molecular Diagnostics Inc is a commercial-stage RNA platform-based life sciences company focused on advancing the promise of precision medicine. Its proprietary NGS-adapted chemistry and HTG EdgeSeq platform automates sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets using a relatively small amount of biological samples, in liquid or solid forms. Its products include instruments, consumables, and software that combine to form its HTG EdgeSeq platform. The company's menu of HTG EdgeSeq molecular profiling panels is automated on its HTG EdgeSeq platform, applying genomic sequencing tools to quickly generate gene expression data using its simplified workflow for customers.
Executives
Stephen Barat officer: Senior VP of Therapeutics C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Thomas W. Dubensky director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
L5 Capital Inc. 10 percent owner 1 FIRST CANADIAN PLACE, 39TH FLOOR, TORONTO A6 M5X 1H3
Christopher P Kiritsy director
Byron Lawson officer: SVP/Chief Commercial Officer C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Tim B Johnson director, officer: President & CEO
Laurence W Lytton 10 percent owner 467 CENTRAL PARK WEST, NY NY 10025
Laura Lee Godlewski officer: VP of Accounting and Reporting C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Shaun D Mcmeans officer: VP, Finance & Admin. & CFO 3708 E COLUMBIA STREET, SUITE #110, TUCSON AZ 85714-3413
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Nv Qiagen 10 percent owner HULSTERWEG 82, PL VENLO P7 5912
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Don M Hardison director

HTG Molecular Diagnostics (HTG Molecular Diagnostics) Headlines